Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2022 Jul 20;22(10):718–725. doi: 10.1016/j.clml.2022.07.010

Figure 3. Incorporation of novel therapeutics into therapy for relapsed/refractory T-ALL/T-LL.

Figure 3.

Blue boxes represent potential opportunities to incorporate novel therapeutics into therapy for relapsed/refractory T-ALL/T-LL. Abbreviations: CAR-T – chimeric antigen receptor T-cell; HSCT – hematopoietic stem cell transplant